
Conference Coverage
Latest Content

New MINT Trial Analysis Favors Liberal Transfusion After MI

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

Drug Development-to-Reimbursement Timelines Show Little Progress Over a Decade

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

A 3-Tier, Immunophenotype-Guided Approach to Overlapping AD and Alopecia Areata

Shorts










Podcasts
Center on Health Equity & Access
All News

Anti-VEGF has maxed out in diabetic macular edema (DME), but Ang-2 and Wnt pathway approaches could target disease differently, said John Kitchens, MD.

CMS value-based payment models underrepresent Black, Hispanic, dual-eligible, and disadvantaged Medicare beneficiaries compared with the broader population.

Our August cover story from Evidence-Based Oncology.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

These results provide support for a potential new standard of care in the relapsed/refractory setting.

Doug Francis of Rhythm Healthcare on what's driving respiratory and mobility care out of facilities and into patients' homes

June delivered 5 FDA firsts; FDA panel weighs peptide access; dermatology absorbs PA costs; Trump sets tariff timeline; digital QI trims LDL-C.

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

June 2026 brought 5 FDA firsts across infectious disease, oncology, and rare disease, expanding treatment options and addressing unmet patient needs.





















